AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine
30 April 2020 -- AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Adenoviruses | AstraZeneca | Clinical Trials | COVID-19 | Oxford University | Pharmaceuticals | Vaccines